The single HDAC therapeutic approach is frequently ineffective in providing sustained tumor suppression because cancer cells can dodge drug-induced effect due to pharmacological resistance, and also because of the toxicity and off-target effects of epi-drugs [130,131,132,133]. This evidence concerns the gene HDAC9 and neoplasm.